ArticleOncogene2026

Metabolic CRISPR screening identifies RPE as a key regulator of acquired enzalutamide resistance through FKBP5 destabilization in prostate cancer.

Jintao Hu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.